(Q24245006)

PubMed

PubMed publication ID

16855976

9 December 2023

Ahmed M Abou-Setta

series ordinal

2

author given names

A M

author last names

Abou-Setta

1 reference

PubMed

PubMed publication ID

16855976

9 December 2023

Mohamed Aboulghar

series ordinal

3

author given names

M

author last names

Aboulghar

1 reference

PubMed

PubMed publication ID

16855976

Cochrane Database of Systematic Reviews

9 December 2023

publication date

19 July 2006

0 references

published in

0 references

cites work

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

GnRH antagonist in IVF poor-responder patients: results of a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin-releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

Association of inhibin B serum levels with parameters of follicular response in a randomized controlled trial comparing gnRH agonist versus antagonist protocols for ovarian hyperstimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles--a prospective, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

7 January 2021

The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

7 January 2021

The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

7 January 2021

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

7 January 2021

Is there a difference in the function of granulosa-luteal cells in patients undergoing in-vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

7 January 2021

A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001750.PUB2

7 January 2021